Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Rivoceranib in Metastatic Thymic Epithelial Tumors
KCT0009148Phase 2Recruiting
- Sponsor
- HLB Cell
- Start
- Oct 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in thymic malignancies (TET), sponsored by HLB Cell. Started Oct 2024; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on KCT0009148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009148.